374,968 Shares in Pfizer Inc. (PFE) Acquired by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. purchased a new stake in Pfizer Inc. (NYSE:PFE) during the third quarter, according to its most recent filing with the SEC. The fund purchased 374,968 shares of the biopharmaceutical company’s stock, valued at approximately $13,386,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Shine Investment Advisory Services Inc. purchased a new position in shares of Pfizer during the 2nd quarter worth about $102,000. Mckinley Capital Management LLC Delaware purchased a new position in shares of Pfizer during the 2nd quarter worth about $103,000. D. Scott Neal Inc. boosted its stake in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares during the period. Herndon Capital Management LLC purchased a new position in shares of Pfizer during the 2nd quarter worth about $120,000. Finally, Private Vista LLC boosted its stake in shares of Pfizer by 2,277.3% during the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 190,933 shares during the period. Institutional investors own 69.74% of the company’s stock.

In other news, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,450 shares of company stock worth $1,065,220. Insiders own 0.06% of the company’s stock.

Several research firms have issued reports on PFE. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price target for the company in a research report on Monday. Morgan Stanley set a $41.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Friday, January 5th. Jefferies Group set a $38.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, October 16th. Finally, Nord/LB reiterated a “neutral” rating on shares of Pfizer in a research note on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $38.83.

Shares of Pfizer Inc. (NYSE PFE) opened at $36.56 on Friday. The firm has a market cap of $219,060.00, a price-to-earnings ratio of 22.43, a PEG ratio of 2.46 and a beta of 1.01. Pfizer Inc. has a 52 week low of $30.90 and a 52 week high of $37.35. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same period in the prior year, the firm posted $0.61 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. research analysts forecast that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

Pfizer announced that its board has initiated a stock buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 3.72%. This is an increase from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.

ILLEGAL ACTIVITY WARNING: This report was first posted by Week Herald and is the property of of Week Herald. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://weekherald.com/2018/01/12/374968-shares-in-pfizer-inc-pfe-purchased-by-crossmark-global-holdings-inc.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply